Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PTCT with free AI briefings, catalyst countdowns, and dilution alerts.

PTCT · PTC THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.1B Cash on Hand
CF+ Cash Runway
Follow PTCT by email Get an email when PTCT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PTCT, unsubscribe in one click. Privacy

📣 What PTCT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sepiapterin
FDA approved Jul 2025 · Sephience
Phenylketonuria Phase 3 · NCT06302348 Recruiting
Deflazacort
FDA approved Feb 2017 · Emflaza
Limb-Girdle Muscular Dystrophy Phase 3 · NCT03783923 Terminated
Levodopa CTNNB1 N/A · NCT07614126 Recruiting
Ataluren Duchenne Muscular Dystrophy Phase 3 · NCT01247207 Terminated
Vatiquinone Friedreich Ataxia Phase 3 · NCT05515536 Active not recruiting
Unesbulin (PTC596) Leiomyosarcoma Phase 2/3 · NCT05269355 Terminated
Emvododstat (PTC299) Pneumonia Phase 2/3 · NCT04439071 Terminated
EPI-589 Amyotrophic Lateral Sclerosis Phase 2 · NCT02460679 Completed
EPI-743 Leigh Syndrome Phase 2 · NCT01721733 Completed
Gene Therapy Agent Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Phase 1/2 · NCT01395641 Completed
PTC844 Rheumatoid Arthritis Phase 2 · NCT07779616 Recruiting
PTC857 Amyotrophic Lateral Sclerosis Phase 2 · NCT05349721 Terminated
Chronic Corticosteroid Therapy Duchenne Muscular Dystrophy Phase 2 · NCT01009294 Terminated
AAV2-hAADC Aromatic Amino Acid Decarboxylase Deficiency Phase 2 · NCT02926066 Completed

Also used in these trials (approved or third-party drugs, not PTCT's own candidates): Dacarbazine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PTCT holds $2.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PTCT files for a raise →

👥 Who Owns PTCT

Insiders 2.9% Institutions (521 holders) 97.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 11,904,696 14.25% 2025-11-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 7,193,433 8.61% 2026-03-31
STATE STREET CORPORATION Institution (13G, 5%+) 5,512,555 6.60% 2026-09-30
Wellington Management Group LLP Institution (13G, 5%+) 5,287,260 6.33% 2026-09-30
Vanguard Portfolio Management Institution (13G, 5%+) 4,871,329 5.83% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 4,284,448 5.13% 2026-03-31
Michael Schmertzler
Director
Insider 1,454,860 1.74% 2026-10-14
Matthew B. Klein
CHIEF EXECUTIVE OFFICER, Director
Insider 383,868 0.46% 2026-08-04
Mark Elliott Boulding
EXEC. VP AND CLO · +47,268 options
Insider 105,272 0.13% 2026-10-09
Pierre Gravier
CHIEF FINANCIAL OFFICER
Insider 83,986 0.10% 2026-07-14
Lee Scott Golden
EVP & CHIEF MEDICAL OFFICER
Insider 79,115 0.09% 2026-04-02
Eric Pauwels
CHIEF BUSINESS OFFICER
Insider 73,411 0.09% 2026-06-10

Share count 83,544,284 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-07-29 — NDA -10.5% +11.2% +17.8%

Browse all historical PDUFA outcomes →

Get the full PTCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.